Ignyta, Inc. – Cancers With NTRK, ROS1, or ALK Gene Fusions

Access Program Information

Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3,
ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise
unable to access, an ongoing clinical trial for entrectinib.